HERON THERAPEUTICS, INC. /DE/ — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
Heron Therapeutics agrees to sell substantially all assets of its pharmaceutical business (aprepitant/granisetron nausea products, bupivacaine/meloxicam pain products) to CorMedix Inc. for base cash consideration of $145 million, 14,583,333 shares of CorMedix common stock, plus royalty and earn-out payments (amounts redacted). Deal includes $2 million escrow and assumes specified liabilities. Requires Heron stockholder approval; CorMedix financing committed.
Why this rating
Asset sale of core business for ~$145M cash plus equity is material—likely 60%+ of Heron's $235M market cap. Transforms company into holding company; significant for trajectory but neutral pending stock price impact of CorMedix shares received and deal execution certainty.
Price action (we called it neutral)
before filing · preread $0.38 ▲ 3.96% | at our read · unknown $0.37 | +10 min · unknown $0.39 ▲ 5.42% | +30 min · unknown $0.37 ▲ 1.36% | +1 hr · unknown $0.39 ▲ 5.15% | +4 hrs · unknown $0.38 ▲ 2.98% |
The stock had already moved -3.81% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.